# Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia

> **NCT01310010** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol de trasplantes hematopoyeticos y terapia celular** · enrollment: 30 (estimated)

## Conditions studied

- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT01310010
- **Lead sponsor:** Grupo Espanol de trasplantes hematopoyeticos y terapia celular
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2015-10
- **Final completion:** 2016-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01310010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01310010, "Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01310010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*